129 related articles for article (PubMed ID: 2838217)
1. In vitro activity of LY146032 against gram-positive bacteria.
Silva M; Jacobus NV; Gorbach SL
Diagn Microbiol Infect Dis; 1988 Feb; 9(2):79-85. PubMed ID: 2838217
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
[TBL] [Abstract][Full Text] [Related]
5. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
Pohlod DJ; Saravolatz LD; Somerville MM
J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
Sillerström E; Wahlund E; Nord CE
J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
[TBL] [Abstract][Full Text] [Related]
7. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Rand KH; Houck HJ
Antimicrob Agents Chemother; 2004 Aug; 48(8):2871-5. PubMed ID: 15273094
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
Chow AW; Cheng N
Antimicrob Agents Chemother; 1988 May; 32(5):788-90. PubMed ID: 2840019
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
10. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Ratner HB; Weeks LS
Antimicrob Agents Chemother; 1987 Jul; 31(7):1014-6. PubMed ID: 2821883
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
13. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method.
Koeth LM; King A; Knight H; May J; Miller LA; Phillips I; Poupard JA
J Antimicrob Chemother; 2000 Sep; 46(3):369-76. PubMed ID: 10980162
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.
Singh KV; Coque TM; Murray BE
Antimicrob Agents Chemother; 1996 Sep; 40(9):2142-6. PubMed ID: 8878596
[TBL] [Abstract][Full Text] [Related]
18. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis.
Miniter PM; Patterson TF; Johnson MA; Andriole VT
Antimicrob Agents Chemother; 1987 Aug; 31(8):1199-203. PubMed ID: 2820299
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
